Lineage Cell Therapeutics, Inc. 8-K

What Happened
On May 12, 2026, Lineage Cell Therapeutics, Inc. (LCTX) filed a Form 8-K under Item 2.02 to announce its results of operations and financial condition for the quarter ended March 31, 2026. The company issued a press release reporting those quarterly results, which is furnished as Exhibit 99.1 to the filing. The report was signed by George A. Samuel III, General Counsel and Corporate Secretary.

Key Details

• Filing date: May 12, 2026.
• Period covered: quarter ended March 31, 2026 (Q1 2026).
• Press release announcing the quarterly results is furnished as Exhibit 99.1.
• The filing also includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.
• No other reportable events (e.g., executive changes, mergers, bankruptcies) were disclosed in this 8-K.

Why It Matters
This 8-K notifies investors that Lineage has released its quarterly earnings/financial results — information that can affect stock valuation, investor sentiment, and liquidity. The Form 8-K itself does not include the financial figures; investors should read the attached press release (Exhibit 99.1) or the company’s investor relations materials for details on revenue, net income/loss, cash position, guidance, or impacts on ongoing programs.